Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxis International Inc.

www.oxis.com

Latest From Fresenius Kabi Oncology Ltd.

FDA’s FY 2013 Drug GMP Warning Letters

Topicals and injectables were the most common types of products to receive drug GMP warning letters in FY 2013. All 43 warning letters are listed here by dosage form with the key issues described.

GSK India Saves Tykerb Main Patent But Loses Claims On Salt Patent To Fresenius Kabi

Amid a series of patent related setbacks faced by global drug firms, GSK has safeguarded Tykerb against Fresenius Kabi.

BioPharmaceutical Asia Pacific

More interest in Indian manufacturing as Fresenius snaps up Parenteral's plant

Parenteral Drugs of India, a manufacturer of intravenous infusions, tablets, syrups and injections, has divested its plant in Goa to Fresenius Kabi for Rs2 billion ($36.7 million), marking ongoing global interest in Indian manufacturing.

India

Alembic rejigs domestic thrust and readies for global generics expansion

Alembic Pharmaceuticals of India is making a conscious shift to chase growth in the chronic and lifestyle segments of the domestic formulations market while de-emphasising the anti-infectives segment, a traditional stronghold. It is also readying for a larger play in the international generics business, as capacity expansions and product approvals roll in.

Metabolic Disorders India
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • DDI Pharmaceuticals
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oxis International Inc.
  • Senior Management
  • Anthony Cataldo, CEO
    Steven Weldon, CFO
  • Contact Info
  • Oxis International Inc.
    Phone: (310) 860-5184
    4830 West Kennedy Blvd.
    Ste. 600
    Tampa, FL 33609
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register